

David Isserman
Investor Relations
(877) 895-5647
ir@nutrapharma.com

NUTRA PHARMA EXPANDS LICENSING AGREEMENT TO INCLUDE ENVIRONMENTAL TESTING FOR NONTUBERCULOUS MYCOBACTERIUM

December 24, 2007 – Boca Raton, FL – Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that it has expanded its licensing agreement with NanoLogix, Inc., (OTC: NNLX) to include intellectual property for the use of testing the environment for NonTuberculosis Mycobacterium (NTM).

“NTM infections are becoming a major concern for hospitals and medical clinics around the world,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Combining our newly licensed intellectual property with our current test kit technology will allow our subsidiary, Designer Diagnostics, to successfully launch a cost-effective solution to help identify the environmental sources of NTM infections,” he added.

NonTuberculous Mycobacterium, also known as atypical Tuberculosis (Atypical TB) or Mycobacterium other than Tuberculosis (MOTT), is a bacteria that is found in water, including hot tubs and showers, some domestic and wild animals, and soil. One of the most common forms of NTM infections found in humans is Mycobacterium avium complex (MAC). This is a primary cause of respiratory disease in humans and is a leading cause of death in HIV/AIDS patients.

“Expanding this licensing agreement to include environmental testing is a natural progression of our relationship with Nutra Pharma and our belief in its ability to successfully bring these kits to market,” commented Bret Barnhizer, President and CEO of NanoLogix, Inc. “In addition to helping detect NTM in patients, Nutra Pharma will now be able to test for NTM in the environment to help prevent others from becoming infected,” he concluded.

Nutra Pharma’s wholly-owned medical devices subsidiary, Designer Diagnostics, is currently undergoing third party validation for its NTM diagnostic test kits at leading Tuberculosis research institute, National Jewish Medical and Research Center, in Denver, Colorado. The Company plans to apply for FDA approval upon successful completion of this clinical trial.

Recently, distinguished NTM research scientist, Dr. Rahul Narang, used the Designer Diagnostics test kits to test soil and water samples collected from the environment of patients with NTM infections. This was the first time the technique was used in India and the findings were presented in November at the 38th Union World Conference on Lung Health in Cape Town, South Africa.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

<http://www.NutraPharma.com>

<http://www.DesignerDiagnostics.com>

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The expanded licensing agreement with NanoLogix, Inc., to include environmental testing should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.